12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ISIS-CRPRx: Phase I data

A Phase I trial in 30 healthy volunteers showed that 400 and 600 mg doses of ISIS-CRPRx given on days 1, 3, 5, 8, 15 and 22 followed by an endotoxin challenge on day 26 significantly reduced...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >